Mga Batayang Estadistika
| CIK | 1796129 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vincerx Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14AINFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rul |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 7, 2025 |
EX-99.1 Exhibit 99.1 Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or el |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14AINFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rul |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14AINFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rul |
|
| May 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num |
|
| May 12, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 28, 2025 |
25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39244 Vincerx Pharma, Inc. The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 18 |
|
| April 17, 2025 |
Exhibit 99.1 Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 San Mateo, California, April 17, 2025 – Vincerx Pharma, Inc. (Nasdaq: VINC) today announced i |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 17, 2025 |
Plan of Liquidation and Dissolution of Vincerx Pharma, Inc. Exhibit 2.1 PLAN OF LIQUIDATION AND DISSOLUTION OF VINCERX PHARMA, INC. The following Plan of Liquidation and Dissolution (the “Plan of Liquidation”), dated as of April 17, 2025, shall effect the dissolution and complete liquidation of Vincerx Pharma, Inc., a Delaware corporation (the “Company”), in accordance with Section 275 and other applicable provisions of the Delaware General Corporation Law |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 3, 2025 |
$100,000,000 Vincerx Pharma, Inc. Debt Securities Common Stock Preferred Stock Depositary Shares Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-284478 PROSPECTUS $100,000,000 Vincerx Pharma, Inc. Debt Securities Common Stock Preferred Stock Depositary Shares Warrants Rights We may, from time to time, offer and sell the securities identified above in one or more offerings. The aggregate initial offering price of all securities sold under this prospectus will not exceed |
|
| April 3, 2025 |
Vincerx Pharma, Inc. Up to $2,707,062 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) File No. 333-284478 PROSPECTUS SUPPLEMENT (To prospectus dated April 2, 2025) Vincerx Pharma, Inc. Up to $2,707,062 Common Stock We have entered into a sales agreement, dated January 21, 2025 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) relating to our common stock, $0.0001 par value per share (“Common Stock”), offered b |
|
| March 31, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| March 31, 2025 |
VINCERX PHARMA, INC. 1825 S. Grant Street San Mateo, California 94402 March 31, 2025 VINCERX PHARMA, INC. 1825 S. Grant Street San Mateo, California 94402 March 31, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Laura Crotty Re: Vincerx Pharma, Inc. - Registration Statement – Form S-3 File No. 333-284478 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pu |
|
| March 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| March 27, 2025 |
Exhibit 19.1 VINCERX PHARMA, INC. INSIDER TRADING POLICY Policy as to Trades in the Company’s Securities by Company Personnel and Treatment of Confidential Information 1. Purpose. Both the Securities and Exchange Commission (the “SEC”) and Congress are very concerned about maintaining the fairness and integrity of the U.S. capital markets. The securities laws are continually reviewed and amended t |
|
| March 27, 2025 |
Second Amended and Restated Certificate of Incorporation, as amended through January 27, 2025. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIFESCI ACQUISITION CORP. December 23, 2020 LifeSci Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware, DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “LifeSci Acquisition Corp.”. The original certificate of incorporation of the corporation was filed with the Secr |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 18, 2025 |
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI EX-99.1 Exhibit 99.1 Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI San Mateo, Calif. – Mar. 18, 2025 (GLOBE NEWSWIRE) – Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing in |
|
| March 18, 2025 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 18, 2025 |
Non-Binding Letter of Intent dated March 14, 2025 EX-10.1 Exhibit 10.1 CONFIDENTIAL Project Falcon Non-Binding Letter of Intent This letter of intent (this “LOI”) sets forth our current proposal with regard to a business combination and associated investment between Vincerx Pharma, Inc. (“Vincerx”) and Global Digital Holdings Inc. (“QumulusAI”) (the “Transaction”). This LOI is an expression of intent only, does not express the final agreement of |
|
| February 28, 2025 |
EX-99.1 Exhibit 99.1 Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives San Mateo, Calif., Feb. 28, 2025 – Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated. As a result, the board of directors w |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 7, 2025 |
Pillsbury Winthrop Shaw Pittman LLP 2550 Hanover Street | Palo Alto, CA 94304-1114 | tel 650. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 6, 2025 |
Amendment #2 to Binding Term Sheet effective as of January 31, 2025 EX-10.1 Exhibit 10.1 AMENDMENT #2 TO BINDING TERM SHEET FOR BUSINESS COMBINATION BETWEEN VINCERX PHARMA, INC. AND OQORY, INC. This AMENDMENT #2 TO BINDING TERM SHEET (this “Amendment”), effective as of January 31, 2025 (the “Amendment Effective Date”), is by and among Vincerx Pharma, Inc., a Delaware corporation (“Vincerx”), Oqory, Inc., a Delaware corporation (“Oqory”), a Delaware corporation (th |
|
| February 6, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 29, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| January 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Vincerx Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1:Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2 |
|
| January 24, 2025 |
Form of Indenture relating to debt securities. Exhibit 4.1 VINCERX PHARMA, INC. TO [ ] Trustee Indenture Dated as of , 20 VINCERX PHARMA, INC. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of , 20 Trust Indenture Act Section Indenture Sections § 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 § 311(a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) § 312(a) 701 |
|
| January 24, 2025 |
As filed with the Securities and Exchange Commission on January 24, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 24, 2025 Registration No. |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 23, 2025 |
Exhibit 99.1 ee Investor Presentation Li nvestor J January anuary 2 23, 3, 22025 025 PHARMA. FORWARD-LOOKING STATEMENTS AND TRADEMARKS FORWARD-LOOKING STATEMENTS No representations or warranties, expressed or implied are given in, or in respect of, this presentation. To the fullest extent permitted by law, in no circumstances will Oqory or Vincerx, or any of their respective subsidiaries, stockhol |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 23, 2025 |
Exhibit 99.1 Vincerx Pharma, Inc. Announces Reverse Stock Split Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 SAN MATEO, California — January 23, 2025 – Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that its board of |
|
| January 21, 2025 |
Sales Agreement dated January 21, 2025 between Vincerx Pharma, Inc. and H.C. Wainwright & Co., LLC. Exhibit 10.1 VINCERX PHARMA, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT January 21, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Vincerx Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as follows: 1. Issuance and Sale of Sha |
|
| January 21, 2025 |
Exhibit 99.1 We have entered into a binding term sheet with Oqory, Inc., a Delaware corporation (“Oqory”), and Vivasor, Inc., Oqory’s parent corporation, relating to a proposed business combination between Vincerx and Oqory. Oqory is a private biopharmaceutical company dedicated to developing next-generation antibody-drug conjugates for the treatment of cancer, focused on the development of Oqory’ |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 21, 2025 |
Vincerx Pharma, Inc. Up to $30,000,000 Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)([5]) File No. 333-262239 PROSPECTUS SUPPLEMENT (To prospectus dated January 28, 2022) Vincerx Pharma, Inc. Up to $30,000,000 Common Stock We have entered into a sales agreement, dated January 21, 2025 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) relating to our common stock, $0.0001 par value per share (“Common Stock” |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 27, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(5) File No. 333-262239 PROSPECTUS SUPPLEMENT (To prospectus dated January 28, 2022) Vincerx Pharma, Inc. 2,816,250 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,635,820 Shares of Common Stock Common Warrants to Purchase up to 10,904,140 Shares of Common Stock Up to 2,635,820 Shares of Common Stock Underlying the Pre-Funded Warrants U |
|
| December 27, 2024 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT VINCERX PHARMA, INC. Warrant Shares: Issue Date: , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the “ |
|
| December 27, 2024 |
EX-99.1 Exhibit 99.1 Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline PALO ALTO, California, December 27, 2024 — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with |
|
| December 27, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT VINCERX PHARMA, INC. Warrant Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| December 27, 2024 |
Binding Term Sheet, as amended EX-10.1 Exhibit 10.1 AMENDMENT #1 TO BINDING TERM SHEET FOR BUSINESS COMBINATION BETWEEN VINCERX PHARMA, INC. AND OQORY, INC. This AMENDMENT #1 TO BINDING TERM SHEET (this “Amendment”), effective as of December 26, 2024 (the “Amendment Effective Date”), is by and among Vincerx Pharma, Inc., a Delaware corporation (“Vincerx”), Oqory, Inc., a Delaware corporation (“Oqory”), a Delaware corporation (t |
|
| December 27, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 26, 2024, between Vincerx Pharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 27, 2024 |
Risks Related to the Proposed Business Combination Exhibit 99.2 Risks Related to the Proposed Business Combination The announced transactions with Oqory and its affiliates may not be consummated on the terms described in the binding term sheet or at all. We have entered into a binding term sheet (the “Term Sheet”) with Oqory, Inc., a Delaware corporation (“Oqory”), and Vivasor, Inc., Oqory’s parent corporation, relating to a proposed business comb |
|
| December 10, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 6, 2024 |
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 Exhibit 99.1 Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 December 4, 2024 Also Exploring Strategic Alternatives to Complement Fundraising Efforts PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
VINC / Vincerx Pharma, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-vinc093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92731L106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| November 14, 2024 |
LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation" ), does hereby make, constitute, and appoint each of Marie Andre, Andres Ortiz Custodio, Kamil Dziedzic, Valerie Ezeagbo, Kelvin Kwo k, Frank Lui, James Todd, Ben Tsoi, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting for th |
|
| November 14, 2024 |
VINC / Vincerx Pharma, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* Vincerx Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92731L106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 13, 2024 |
VINC / Vincerx Pharma, Inc. / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d892826dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VINCERX PHARMA, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92731L106 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Chec |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2024 |
Exhibit 99.1 Vincerx Pharma Reports Third Quarter 2024 Financial Results Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1 dose-escalation studies of small molecule drug-conjugate (SMDC), VIP236, and CDK9 inhibitor, enitociclib, and identified the maximu |
|
| November 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| November 5, 2024 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 30, 2024 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 3) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Vincerx Pharma, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 92731L106 (C |
|
| September 10, 2024 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Vincerx Pharma, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 92731L106 (C |
|
| September 10, 2024 |
Form of Email Announcement Regarding Extension of the Exchange Offer Exhibit (a)(1)(L) To: Eligible Holders CC: Gabriela Jairala Subject: Update: Extension of Period to Exchange Eligible Options for New Restricted Stock Units (RSUs) Hello everyone, Please be aware that Vincerx’s Compensation Committee has extended the expiration time of the Exchange Offer to 5:00 p. |
|
| August 19, 2024 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Vincerx Pharma, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 92731L106 (C |
|
| August 19, 2024 |
Stock Option Repricing and Exchange Program Presentation Exhibit (a)(1)(K) Vincerx Stock Option Repricing and Exchange Program 19 August 2024 CONFIDENTIAL Purpose of Stock Option Repricing and Exchange Program Prior to the repricing, all Vincerx stock options were “underwater” (i. |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 13, 2024 |
Exhibit (a)(1)(H) FORM OF CONFIRMATION LETTER TO ELIGIBLE HOLDERS PARTICIPATING IN THE EXCHANGE CONFIRMING ACCEPTANCE OF ELIGIBLE OPTIONS Date: [], 2024 To: [] From: Vincerx Pharma, Inc. |
|
| August 13, 2024 |
Form of Reminder Email to Eligible Holders Exhibit (a)(1)(G) Subject: REMINDER – Vincerx Pharma, Inc. Offer to Exchange Eligible Options for New Restricted Stock Units To: Eligible Holders Date: [], 2024 This email is intended to serve as a reminder that we are nearing the expiration of the Exchange Offer described in the Offer to Exchange Eligible Options for New Restricted Stock Units dated August 13, 2024 (the “Exchange Offer”). The Exc |
|
| August 13, 2024 |
Exhibit (a)(1)(J) [NAME] [ADDRESS] [DATE] Re: Repricing of Stock Options Dear : I am pleased to announce that the Board of Directors of Vincerx Pharma, Inc. |
|
| August 13, 2024 |
Exhibit (a)(1)(F) FORM OF COMMUNICATION TO ELIGIBLE HOLDERS CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM Date: [], 2024 To: [] From: Vincerx Pharma, Inc. |
|
| August 13, 2024 |
Form of New RSU Grant Notice and Agreement Exhibit (a)(1)(I) Replacement RSU VINCERX PHARMA, INC. 2020 STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD You are receiving the following Restricted Stock Units (the “Restricted Stock Units,” “RSUs” or this “Award”) pursuant to your election to participate in the Offer to Exchange Eligible Options for New Restricted Stock Units dated August 13, 2024, under which you surrendered option |
|
| August 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Schedule TO-I (Form Type) Vincerx Pharma, Inc. |
|
| August 13, 2024 |
Exhibit (a)(1)(E) FORM OF COMMUNICATION TO ELIGIBLE HOLDERS PARTICIPATING IN THE EXCHANGE OFFER CONFIRMING RECEIPT OF ELECTION FORM Date: [], 2024 To: [] From: Vincerx Pharma, Inc. |
|
| August 13, 2024 |
Notice of Withdrawal of Election Form Exhibit (a)(1)(D) VINCERX PHARMA, INC. NOTICE OF WITHDRAWAL OF ELECTION FORM INSTRUCTIONS If you previously elected to accept the offer by Vincerx Pharma, Inc. (“Vincerx”) to exchange some or all of your outstanding Eligible Options for New RSUs, subject to the terms and conditions set forth in the Offer to Exchange Eligible Options for New Restricted Stock Units dated August 13, 2024 (the “Exchan |
|
| August 13, 2024 |
Form of Email Announcement of Offer to Exchange Exhibit (a)(1)(B) Subject: Vincerx Pharma, Inc. Offer to Exchange Eligible Options for New Restricted Stock Units To: Eligible Holders Date: August 13, 2024 We are pleased to announce that Vincerx Pharma, Inc. (“Vincerx”) is commencing an Offer to Exchange Eligible Options for New Restricted Stock Units (referred to as the “Exchange Offer”) today, Tuesday, August 13, 2024. The Exchange Offer progr |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Vincerx Pharma, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 92731L106 (CUSIP Number of Common Stock Un |
|
| August 13, 2024 |
Exhibit (a)(1)(C) ELECTION FORM Before signing this Election Form, please make sure you have received, read and understand the documents that make up this offer, including (1) the Offer to Exchange Eligible Options for New Restricted Stock Units dated August 13, 2024 filed with the U. |
|
| August 13, 2024 |
Offer to Exchange Eligible Options for New Restricted Stock Units, dated August 13, 2024 Exhibit (a)(1)(A) VINCERX PHARMA, INC. 260 SHERIDAN AVENUE, SUITE 400 PALO ALTO, CALIFORNIA 94306 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS VINCERX PHARMA, INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS This offer and withdrawal rights will expire at 5:00 p.m., U.S. Pacific Time, on Wednesday, September 11, 2024, unless |
|
| August 8, 2024 |
Exhibit 99.1 Vincerx Pharma Reports Second Quarter 2024 Financial Results Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024 Expected cash runway through 2024 PALO ALTO, Calif., August 8, 2024 – Vincerx Pharma, Inc. (Nasdaq: VINC) |
|
| August 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| July 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 28, 2024 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 21, 2024 |
As filed with the Securities and Exchange Commission on June 21, 2024 S-8 As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| June 21, 2024 |
Exhibit 99.1 VINCERX PHARMA, INC. 2020 STOCK INCENTIVE PLAN (As amended on March 7, 2024) TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. DEFINITIONS 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Award Agreement” 1 (d) “Board of Directors” or “Board” 1 (e) “Cash-Based Award” 1 (f) “Change in Control” 1 (g) “Code” 3 (h) “Committee” 3 (i) “Company” 3 (j) “Consultant” 3 (k) “Disabil |
|
| June 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vincerx Pharma, Inc. |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 28, 2024 |
Amended and Restated Bylaws, as amended as of May 23, 2024 EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VINCERX PHARMA, INC. (formerly known as Vincera Pharma, Inc.) (a Delaware corporation) (As amended as of May 23, 2024) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 3 2.4 Notice of Meetings 3 2.5 List of Stoc |
|
| May 14, 2024 |
Exhibit 99.1 Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti- CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive results from en |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| May 3, 2024 |
VINC / Vincerx Pharma, Inc. / Prosight Management, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VINCERX PHARMA, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92731L106 (CUSIP Number) April 25, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| May 3, 2024 |
JOINT FILING AGREEMENT May 3, 2024 EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT May 3, 2024 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including |
|
| April 29, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(5) File No. 333-262239 PROSPECTUS SUPPLEMENT (To prospectus dated January 28, 2022) Vincerx Pharma, Inc. 6,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 16,000,000 Shares of Common Stock Warrants to Purchase up to 22,000,000 Shares of Common Stock We are offering 6,000,000 shares of our common stock, $0.0001 par value per share |
|
| April 26, 2024 |
Exhibit 4.2 WARRANT TO PURCHASE COMMON STOCK VINCERX PHARMA, INC. Number of Warrant Shares: Issue Date: [ ], 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prio |
|
| April 26, 2024 |
Exhibit 4.1 VINCERX PHARMA, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2024 Vincerx Pharma, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 26, 2024 |
Exhibit 1.1 Execution Version VINCERX PHARMA, INC. (a Delaware corporation) 6,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 16,000,000 Shares of Common Stock Warrants to Purchase 22,000,000 Shares of Common Stock UNDERWRITING AGREEMENT April 25, 2024 Leerink Partners LLC as Representative of the several Underwriters c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor |
|
| April 26, 2024 |
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants Exhibit 99.1 Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants PALO ALTO, California, April 25, 2024 — Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) |
|
| April 25, 2024 |
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants Exhibit 99.1 Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants PALO ALTO, CA, April 25, 2024 — Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shar |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 25, 2024 |
SUBJECT TO COMPLETION, DATED APRIL 25, 2024 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) File No. 333-262239 The information in this prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, an |
|
| April 10, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2024 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 29, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation. Exhibit 97.1 VINCERX PHARMA, INC. INCENTIVE-BASED COMPENSATION RECOUPMENT POLICY 1. Purpose The Board of Directors (the “Board”) of Vincerx Pharma, Inc., a Delaware corporation (the “Company”), has adopted this Incentive-Based Compensation Recoupment Policy (this “Policy”) to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10 |
|
| March 29, 2024 |
Vincerx Pharma, Inc. Up to $50,000,000 Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration no. 333-262239 PROSPECTUS SUPPLEMENT (To prospectus dated January 28, 2022) Vincerx Pharma, Inc. Up to $50,000,000 Common Stock We have entered into a sales agreement, dated March 29, 2024 (the “Sales Agreement”), with Leerink Partners LLC (“Leerink Partners”), relating to our common stock, $0.0001 par value per share (“Common S |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 29, 2024 |
Exhibit 21.1 Subsidiaries of Vincerx Pharma, Inc. Subsidiary Jurisdiction VNRX Corp. Delaware Vincerx Pharma GmbH Germany Vincerx Pharma Australia Pty. Australia |
|
| March 29, 2024 |
Exhibit 99.1 Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial ongoing for VIP943, a best-in-class anti-CD123 antibody-drug conjugate (AD |
|
| March 29, 2024 |
Exhibit 10.1 VINCERX PHARMA, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT March 29, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Vincerx Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance and S |
|
| March 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f |
|
| February 14, 2024 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the |
|
| February 14, 2024 |
VINC / Vincerx Pharma, Inc. / Long Focus Capital Management, Llc - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vincerx Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92731L106 (CUSIP Number) Long Focus Capital Management LLC 207 Calle Del Parque A&M Tower, 8th Floor San Juan, PR 00912 (787) 333-0240 (Name, Address and Telephone Number o |
|
| February 13, 2024 |
VINC / Vincerx Pharma, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Vincerx Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92731L106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 13, 2024 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Szabina Biro, Hannah Chae, Andres Ortiz Custodio, Kamil Dziedzic, Krishnan Harihanran, Kelvin Kwok, Frank Lui, James Todd, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting |
|
| February 13, 2024 |
SC 13G/A 1 vincerxsch13ga-021324.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92731L106 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 14, 2023 |
Exhibit 99.1 Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose escalation for VIP236 - first-in-class small molecule-drug conjugate (SMDC) for treatment of solid |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2023 |
EX-99.1 Exhibit 99.1 Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC Cash balance expected to support planned operations into late 2024 PALO ALTO, California, August |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 7, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 11, 2023 |
EX-99.1 Exhibit 99.1 Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class αvb3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation antibody-drug conjugate (ADC), for treatment of CD123+ hematologic malignancies on track |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 12, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2023 |
DEFA14A 1 d433579ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| March 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vincerx Pharma, Inc. |
|
| March 28, 2023 |
EX-99.1 Exhibit 99.1 Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an αvß3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate (ADC) VIP943 remains on track for mid-2023; expected to be in clinic in the second ha |
|
| March 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-392 |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 S-8 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 14, 2023 |
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP EX-2 3 ex2.htm EXHIBIT 2 Exhibit 2 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Long Focus Capital Management, LLC, a Delaware single member limited liability company Long Focus Capital Master, LTD., a Cayman Islands limited company Condagua, LLC, a Delaware single member limited liability company John B. Helmers, a United States citizen A. Glenn Helmers, a United States citizen |
|
| February 14, 2023 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the |
|
| February 14, 2023 |
VINC / Vincera Pharma, Inc. / Long Focus Capital Management, Llc - SC 13G Passive Investment SC 13G 1 vincerx13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vincerx Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92731L106 (CUSIP Number) Long Focus Capital Management LLC 207 Calle Del Parque A&M Tower, 8th Floor San Juan, PR 00912 (787) 333-0240 (Name, |
|
| February 13, 2023 |
SC 13G/A 1 vinc-sc13ga021323.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92731L106 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 |
|
| February 10, 2023 |
VINC / Vincera Pharma, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm235947d11sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92731L106 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the app |
|
| January 3, 2023 |
Exhibit 17.2 Ahmed Handy MD Chairman of the Board of Directors and CEO Vincerx Corporation Dear Vincerx team I am writing to tender my resignation from the Board of Directors of Vincerx Corporation (the ?Company?), effective December 31, 2022. My decision to resign from the Company?s board of directors is the result of assessing the company strategy, upon which our views differ. I do not have any |
|
| January 3, 2023 |
Exhibit 17.1 Ahmed Handy MD Chairman of the Board of Directors and CEO Vincerx Corporation Dear Vincerx team I am writing to tender my resignation from the Board of Directors of Vincerx Corporation (the ?Company?), effective December 31, 2022. My decision to resign from the Company?s board of directors is the result of assessing the company strategy, upon which our views differ. I do not have any |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 29, 2022 |
VINC / Vincera Pharma, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 10, 2022 |
Exhibit 99.1 Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update Received Orphan Drug Designation for enitociclib; continue to focus on priority indications IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 expected by year-end IND filings for antibody drug conjugates (ADCs), VIP943 and VIP924, remain on track for 2H2023 and 1H202 |
|
| November 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2022 |
Consulting Agreement dated August 19, 2022 with LifeSci Consulting, LLC. Exhibit 10.1 August 10, 2022 Vincerx Pharma, Inc. 260 Sheridan Avenue, Suite #400 Palo Alto, California 94306 Attn: Ahmed Hamdy, M.D. Dr. Hamdy: This letter (?Agreement?) confirms our understanding that Vincerx Pharma, Inc., (the ?Company?) has engaged LifeSci Consulting, LLC (?LifeSci?), to act as its non-exclusive advisor with respect to the Company?s effort to secure strategic collaboration or |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 11, 2022 |
Exhibit 99.1 Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND filings for antibody drug conjugates (ADCs), VIP943 and VIP924, remain on track for 2H2023 and |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 7, 2022 |
Exhibit 99.1 Vincerx Pharma Provides Key Strategic Update Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND filings for VIP236 in 2H22 and for VIP943 in 2H23 remain on track Streamlining and realigning resources to support key indications and programs; extending estimated cash runway into late 2024 P |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 12, 2022 |
Exhibit 99.1 Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic malignancies in poster at AACR Annual Meeting Continues to execute on Phase 1b VIP152 clinical studies; on track to initiate Phase 2 VIP152 stud |
|
| April 12, 2022 |
DEFA14A 1 d328531ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 12, 2022 |
DEF 14A 1 d429793ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| March 29, 2022 |
As filed with the Securities and Exchange Commission on March 29, 2022 As filed with the Securities and Exchange Commission on March 29, 2022 Registration No. |
|
| March 29, 2022 |
Exhibit 4.7 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The paragraphs below describe the common stock of Vincerx Pharma, Inc. (the ?Company?). The following summary of the material terms of our common stock is not intended to be a complete summary of the rights and preferences of such common stock, and is qualified by reference to our Second |
|
| March 29, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Vincerx Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 29, 2022 |
Exhibit 99.1 Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as a poster at upcoming AACR Annual Meeting in April 2022 Anticipate initiating Phase 2 studies of VIP152 in 2H2022 IND filing f |
|
| March 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-392 |
|
| February 14, 2022 |
VINC / Vincera Pharma, Inc. / RTW INVESTMENTS, LP - VINCERX PHARMA, INC. Passive Investment SC 13G/A 1 p22-0722sc13ga.htm VINCERX PHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92731L106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check |
|
| February 14, 2022 |
VINC / Vincera Pharma, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
VINC / Vincera Pharma, Inc. / Affinity Asset Advisors, LLC - AMENDED SC 13G Passive Investment SC 13G/A 1 vincerx-sc13ga020822.htm AMENDED SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92731L106 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 Third |
|
| February 10, 2022 |
VINC / Vincera Pharma, Inc. / Rubric Capital Management LP - VINCERX PHARMA, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92731L106 (CUSIP Number) January 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| January 28, 2022 |
$150,000,000 Vincerx Pharma, Inc. Debt Securities Common Stock Preferred Stock Depositary Shares 424B3 1 d204497d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-262239 PROSPECTUS $150,000,000 Vincerx Pharma, Inc. Debt Securities Common Stock Preferred Stock Depositary Shares Warrants Rights We may, from time to time, offer and sell the securities identified above in one or more offerings. The aggregate initial offering price of all securities sold under |
|
| January 26, 2022 |
VINCERX PHARMA, INC. 260 Sheridan Avenue, Suite 400 Palo Alto, CA 94306 January 26, 2022 CORRESP 1 filename1.htm VINCERX PHARMA, INC. 260 Sheridan Avenue, Suite 400 Palo Alto, CA 94306 January 26, 2022 VIA FACSIMILE AND EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vincerx Pharma, Inc. - Registration Statement – Form S-3 File No. 333-262239 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 19 |
|
| January 19, 2022 |
Exhibit 4.1 VINCERX PHARMA, INC. TO [ ] Trustee Indenture Dated as of , 20 VINCERX PHARMA, INC. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of , 20 Trust Indenture Act Section Indenture Sections ? 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 ? 311(a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) ? 312(a) 701 702(a) ( |
|
| January 19, 2022 |
As filed with the Securities and Exchange Commission on January 19, 2022 Table of Contents As filed with the Securities and Exchange Commission on January 19, 2022 Registration No. |
|
| January 11, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-252589 PROSPECTUS Vincerx Pharma, Inc. Up to 5,562,878 Shares of Common Stock Up to 3,295,000 Shares of Common Stock Issuable Upon Exercise of Private Warrants Up to 3,295,000 Private Warrants This prospectus relates to the issuance by us of up to an aggregate of 3,295,000 shares of our common stock, $0.0001 par value per share, issua |
|
| January 11, 2022 |
Vincerx Pharma, Inc. 3,176,910 Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-260246 PROSPECTUS Vincerx Pharma, Inc. 3,176,910 Shares Common Stock This prospectus relates to the offer and sale from time to time by the Selling Stockholders named in this prospectus of up to 3,176,910 shares of common stock. The shares of common stock have been issued pursuant to a Securities Purchase Agreement, or the Purchase Ag |
|
| January 7, 2022 |
As filed with the Securities and Exchange Commission on January 6, 2022 POS AM 1 d276244dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on January 6, 2022 Registration No. 333-252589 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vincerx Pharma, Inc. (Exact Name of Registrant as Specified in it |
|
| January 7, 2022 |
As filed with the Securities and Exchange Commission on January 6, 2022 Table of Contents As filed with the Securities and Exchange Commission on January 6, 2022 Registration No. |
|
| November 22, 2021 |
SC 13G 1 vincerx-sc13g111021.htm ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vincerx Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92731L106 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenbla |
|
| November 12, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-252589 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Prospectus? |
|
| November 12, 2021 |
Vincerx Pharma, Inc. Up to 3,500,000 Shares of Common Stock 424B3 1 d187519d424b3.htm 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-260246 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated October 25, 2021) Vincerx Pharma, Inc. Up to 3,500,000 Shares of Common Stock This prospectus supplement supplements the prospectus dated October 25, 2021 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-260 |
|
| November 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2021 |
Exhibit 99.1 Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a Corporate Update Advancing Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Strengthened balance sheet wit |
|
| October 26, 2021 |
3,500,000 Shares Vincerx Pharma, Inc. Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-260246 PROSPECTUS 3,500,000 Shares Vincerx Pharma, Inc. Common Stock This prospectus relates to the offer and sale from time to time by the Selling Stockholders named in this prospectus of up to 3,500,000 shares of common stock. The shares of common stock have been issued pursuant to a Securities Purchase Agreement, or the Purchase Ag |
|
| October 21, 2021 |
VINCERX PHARMA, INC. 260 Sheridan Avenue, Suite 400 Palo Alto, CA 94306 October 21, 2021 VINCERX PHARMA, INC. 260 Sheridan Avenue, Suite 400 Palo Alto, CA 94306 October 21, 2021 VIA FACSIMILE AND EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vincerx Pharma, Inc. - Registration Statement – Form S-1 File No. 333-260246 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vincerx |
|
| October 14, 2021 |
Exhibit 10.11 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?), dated as of December 23, 2020, is by and between Vincera Pharma, Inc., a Delaware corporation (the ?Company?), and Xiaoming Zhang (?Executive?). WHEREAS, the Company wishes to retain the services of Executive and Executive wishes to be employed by the Company on the terms and subject to the conditio |
|
| October 14, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on October 14, 2021 Registration No. |
|
| October 14, 2021 |
Exhibit 10.10 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?), dated as of December 23, 2020, is by and between Vincera Pharma, Inc., a Delaware corporation (the ?Company?), and Sooin Hwang, PhD (?Executive?). WHEREAS, the Company wishes to retain the services of Executive and Executive wishes to be employed by the Company on the terms and subject to the condit |
|
| September 28, 2021 |
VINC / Vincera Pharma, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| September 17, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Prospectus?), which f |
|
| September 16, 2021 |
Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of September 15, 2021 by and among Vincerx Pharma, Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of September 15, 2021 (the ?Purchase Agreement?). Capi |
|
| September 16, 2021 |
Exhibit 99.1 Vincerx Pharma Announces $50 Million Private Placement Strengthened financial position extends expected cash runway into 2023 PALO ALTO, Calif., September 16, 2021 (GLOBE NEWSWIRE) ? Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announced that it has entered i |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 16, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of September 15, 2021 by and among Vincerx Pharma, Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Company and the Investors are executing and deliv |
|
| August 12, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Pros |
|
| August 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 12, 2021 |
Exhibit 99.1 Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 PALO ALTO, Calif |
|
| August 4, 2021 |
VINC / Vincera Pharma, Inc. / SAGE RHINO CAPITAL LLC - SAGE RHINO CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Vincerx Pharma Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92731L106 (CUSIP Number) March 04, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rul |
|
| June 11, 2021 |
Table of Contents Exhibit 99.1 VINCERX PHARMA, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (Adopted by the Board of Directors on February 11, 2021) (Approved by the Stockholders on May 13, 2021) (Effective on May 13, 2021) Table of Contents Table of Contents Page SECTION 1 Purpose Of The Plan 4 SECTION 2 Definitions 4 (a) ?Board? 4 (b) ?Code? 4 (c) ?Committee? 4 (d) ?Company? 4 (e) ?Compensation? 4 (f) |
|
| June 11, 2021 |
As filed with the Securities and Exchange Commission on June 11, 2021 As filed with the Securities and Exchange Commission on June 11, 2021 Registration No. |
|
| May 17, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Pros |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 17, 2021 |
Exhibit 99.1 Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 First patient in Phase 1b Study of VIP152 in MYC-driven R/R aggressive lymphomas and advanced solid tumors expected 2Q 2021 Phase 1 VIP152 dose-escal |
|
| May 14, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Pros |
|
| May 14, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Prospectus?), which fo |
|
| May 14, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 6, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Prospectus?), which fo |
|
| April 20, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Prospectus?), which fo |
|
| April 20, 2021 |
Exhibit 99.1 Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Vincerx?s second clinical program for potential best-in-class CDK9 inhibitor First patient in Phase 1b Study in MYC-driven R/R aggre |
|
| April 20, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 5, 2021 |
NOTICE OF REDEMPTION OF CERTAIN WARRANTS (CUSIP 92731L114) Exhibit 99.2 April 5, 2021 NOTICE OF REDEMPTION OF CERTAIN WARRANTS (CUSIP 92731L114) Dear Public Warrant Holder, Vincerx Pharma, Inc. (the ?Company?) hereby gives notice that it is redeeming, at 5:00 p.m. New York City time on May 5, 2021 (the ?Redemption Date?), all of the Company?s outstanding public warrants (the ?Public Warrants?) to purchase shares of the Company?s common stock, $0.0001 par |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 5, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Prospectus?), which fo |
|
| April 5, 2021 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VINCERX PHARMA, INC. (formerly known as Vincera Pharma, Inc.) (a Delaware corporation) (As amended as of April 2, 2021) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 3 2.4 Notice of Meetings 3 2.5 List of Stockholde |
|
| April 5, 2021 |
Vincerx Pharma Announces Redemption of Public Warrants Exhibit 99.1 Vincerx Pharma Announces Redemption of Public Warrants PALO ALTO, California, April 5, 2021 ? Vincerx Pharma, Inc. (Nasdaq: VINC) (the ?Company?), today announced that it will redeem all of its outstanding public warrants (the ?Public Warrants?) to purchase shares of the Company?s common stock, $0.0001 par value per share (?Common Stock?), that were issued under the Warrant Agreement, |
|
| March 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 24, 2021 |
Exhibit 99.1 Vincerx Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update License agreement with Bayer AG secures oncology portolio including clinical-stage PTEFb/CDK9 inhibitor with encouraging Phase 1 activity Successful completion of business combination transaction, raising approximately $62 million Strengthened leadership with appointments of Chie |
|
| March 22, 2021 |
Exhibit 4.6 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The paragraphs below describe the units, common stock, and public warrants of Vincerx Pharma, Inc. (the ?Company?). The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by |
|
| March 22, 2021 |
EX-10.8 4 d132337dex108.htm EX-10.8 Exhibit 10.8 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of January 27, 2021, is by and between Vincerx Pharma, Inc., a Delaware corporation (the “Company”), and Tom C. Thomas (“Executive”). WHEREAS, the Company wishes to retain the services of Executive and Executive wishes to be employed by the Company on the |
|
| March 22, 2021 |
Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?), dated as of December 23, 2020, is by and between Vincera Pharma, Inc., a Delaware corporation (the ?Company?), and Hermes Garban (?Executive?). WHEREAS, the Company wishes to retain the services of Executive and Executive wishes to be employed by the Company on the terms and subject to the conditions |
|
| March 22, 2021 |
As filed with the Securities and Exchange Commission on March 22, 2021 Registration No. |
|
| March 22, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-252589 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated February 9, 2021) Vincerx Pharma, Inc. Up to 6,112,884 Shares of Common Stock Up to 6,851,883 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 3,570,000 Private Warrants This prospectus supplement supplements the prospectus dated February 9, 2021 (the ?Pros |
|
| March 22, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-392 |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission |
